Análise da Máquina de Turing Persistente com múltiplas fitas de trabalho

Nos últimos 70 anos têm sido apresentadas várias propostas para caracteriza ção da noção intuitiva de computabilidade. O modelo de Computação mais conhecido para expressar a noção intuitiva de algoritmo é a Máquina de Turing. Esse trabalho apresenta máquinas abstratas que representam diferentes formas de comportamento computacional, sendo possível abordar a diversidade entre a Teoria da Computação Clássica (Máquina de Turing) e a Teoria da Computa- ção Interativa (Máquina de Turing Persistente). Com a evolução dos sistemas de computação, surgiu a necessidade de estender a de nição de Máquina de Turing para tratar uma diversidade de novas situações, esses problemas conduziram a uma mudança de paradigma. Neste contexto foi desenvolvido a Máquina de Turing Persistente, que é capaz de fundamentar a Teoria da Computação Interativa. Máquinas de Turing Persistentes (PeTM) são modelos que expressam comportamento interativo, esse modelo é uma extensão da Máquina de Turing. O presente trabalho tem como objetivo explorar paralelismo na Máquina de Turing Persistente, através da formalização de uma extensão paralela da PeTM e o estudo dos efeitos sobre essa extensão, variando o número de tas de trabalho. Contribui- ções desse trabalho incluem a de nição de uma máquina de Turing Persistente Paralela para modelar computação interativa e uma exposição de conceitos fundamentais e necessários para o entendimento desse novo paradigma. Os métodos e conceitos apresentados para formalização da computação na Máquina de Turing Persistente Paralela desenvolvidos nessa dissertação, podem servir como base para uma melhor compreensão da Teoria da Computação Interativa e da forma como o paralelismo pode ser especi cado em modelos teóricos.

Turing and the Trans-Pacific Partnership: Intellectual Property, Public Health, and Access to Essential Medicines

A recent controversy in the United States over drug pricing by Turing Pharmaceuticals AG has raised larger issues in respect of intellectual property, access to medicines, and the Trans-Pacific Partnership (TPP). In August 2015, Turing Pharmaceuticals AG – a private biopharmaceutical company with offices in New York, the United States, and Zug, Switzerland - acquired the exclusive marketing rights to Daraprim in the United States from Impax Laboratories Incorporated. Martin Shkreli, Turing’s Founder and Chief Executive Officer, maintained: “The acquisition of Daraprim and our toxoplasmosis research program are significant steps along Turing’s path of bringing novel medications to patients with serious disorders, some of whom often go undiagnosed and untreated.” He emphasised: “We intend to invest in the development of new drug candidates that we hope will yield an even better clinical profile, and also plan to launch an educational effort to help raise awareness and improve diagnosis for patients with toxoplasmosis.” In September 2015, there was much public controversy over the decision of Martin Shkreli to raise the price of a 62 year old drug, Daraprim, from $US13.50 to $US750 a pill. The drug is particularly useful in respect to the treatment and prevention of malaria, and in the treatment of infections in individuals with HIV/AIDS. Daraprim is listed on the World Health Organization’s (WHO) List of Essential Medicines. In the face of much criticism, Martin Shkreli has said that he will reduce the price of Daraprim. He observed: “We've agreed to lower the price on Daraprim to a point that is more affordable and is able to allow the company to make a profit, but a very small profit.” He maintained: “We think these changes will be welcomed.” However, he has been vague and ambiguous about the nature of the commitment. Notably, the lobby group, Pharmaceutical Research and Manufacturers of America (PhARMA), disassociated itself from the claims of Turing Pharmaceuticals. The group said: “PhRMA members have a long history of drug discovery and innovation that has led to increased longevity and improved lives for millions of patients.” The group noted: “Turing Pharmaceutical is not a member of PhRMA and we do not embrace either their recent actions or the conduct of their CEO.” The biotechnology peak body Biotechnology Industry Organization also sought to distance itself from Turing Pharmaceuticals. A hot topic: United States political debate about access to affordable medicines This controversy over Daraprim is unusual – given the age of drug concerned. Daraprim is not subject to patent protection. Nonetheless, there remains a monopoly in respect of the marketplace. Drug pricing is not an isolated problem. There have been many concerns about drug pricing – particularly in respect of essential medicines for HIV/AIDS, tuberculosis, and malaria. This recent controversy is part of a larger debate about access to affordable medicines. The dispute raises larger issues about healthcare, consumer rights, competition policy, and trade. The Daraprim controversy has provided impetus for law reform in the US. US Presidential Candidate Hillary Clinton commented: “Price gouging like this in this specialty drug market is outrageous.” In response to her comments, the Nasdaq Biotechnology Index fell sharply. Hillary Clinton has announced a prescription drug reform plan to protect consumers and promote innovation – while putting an end to profiteering. On her campaign site, she has emphasised that “affordable healthcare is a basic human right.” Her rival progressive candidate, Bernie Sanders, was also concerned about the price hike. He wrote a letter to Martin Shkreli, complaining about the price increase for the drug Daraprim. Sanders said: “The enormous, overnight price increase for Daraprim is just the latest in a long list of skyrocketing price increases for certain critical medications.” He has pushed for reforms to intellectual property to make medicines affordable. The TPP and intellectual property The Daraprim controversy and political debate raises further issues about the design of the TPP. The dispute highlights the dangers of extending the rights of pharmaceutical drug companies under intellectual property, investor-state dispute settlement, and drug administration. Recently, the civil society group Knowledge Ecology International published a leaked draft of the Intellectual Property Chapter of the TPP. Knowledge Ecology International Director, James Love, was concerned the text revealed that the US “continues to be the most aggressive supporter of expanded intellectual property rights for drug companies.” He was concerned that “the proposals contained in the TPP will harm consumers and in some cases block innovation.” James Love feared: “In countless ways, the Obama Administration has sought to expand and extend drug monopolies and raise drug prices.” He maintained: “The astonishing collection of proposals pandering to big drug companies make more difficult the task of ensuring access to drugs for the treatment of cancer and other diseases and conditions.” Love called for a different approach to intellectual property and trade: “Rather than focusing on more intellectual property rights for drug companies, and a death-inducing spiral of higher prices and access barriers, the trade agreement could seek new norms to expand the funding of medical research and development (R&D) as a public good, an area where the US has an admirable track record, such as the public funding of research at the National Institutes of Health (NIH) and other federal agencies.” In addition, there has been much concern about the Investment Chapter of the TPP. The investor-state dispute settlement regime would enable foreign investors to challenge government policy making, which affected their investments. In the context of healthcare, there is a worry that pharmaceutical drug companies will deploy their investor rights to challenge public health measures – such as, for instance, initiatives to curb drug pricing and profiteering. Such concerns are not merely theoretical. Eli Lilly has brought an investor action against the Canadian Government over the rejection of its drug patents under the investor-state dispute settlement regime of the North American Free Trade Agreement (NAFTA). The Health Annex to the TPP also raises worries that pharmaceutical drug companies will able to object to regulatory procedures in respect of healthcare. It is disappointing that the TPP – in the leaks that we have seen – has only limited recognition of the importance of access to essential medicines. There is a need to ensure that there are proper safeguards to provide access to essential medicines – particularly in respect of HIV/AIDs, malaria, and tuberculosis. Moreover, there must be protection against drug profiteering and price gouging in any trade agreement. There should be strong measures against the abuse of intellectual property rights. The dispute over Turing Pharmaceuticals AG and Daraprim is an important cautionary warning in respect of some of the dangers present in the secret negotiations in respect of the TPP. There is a need to preserve consumer rights, competition policy, and public health in trade negotiations over an agreement covering the Pacific Rim.

Turing and animal coat patterns

The present article describes a beautiful contribution of Alan Turing to our understanding of how animal coat patterns form. The question that Turing posed was the following. A collection of identical cells (or processors for that matter), all running the exact same program, and all communicating with each other in the exact same way, should always be in the same state. Yet they produce nonhomogeneous periodic patterns, like those seen on animal coats. How does this happen? Turing gave an elegant explanation for this phenomenon, namely that differences between the cells due to small amounts of random noise can actually be amplified into structured periodic patterns. We attempt to describe his core conceptual contribution below.

Starbog: The Garden Virtuoso and the Turing Machine

This article will discuss a recent ensemble composition entitled Starbog which was toured and broadcast in Britain in 2006 . The composition of Starbog focused on developing working methods which combined computer-based techniques (using OpenMusic) with more subconscious means of generating musical ideas. The challenge in achieving this was as much aesthetic/philosophical as it was technical and the present article is intending as a ‘sounding’ which focuses on the influence OpenMusic has had on the composer’s music, rather than documenting the nature of the often simple application of algorithms.

The darmstadt challenge (the turing test revisited)

Significant work has been done in the areas of Pervcomp/Ubicomp Smart Environments with advances on making proactive systems, but those advances have not made these type of systems accurately proactive. On the other hand a great deal is needed to make systems more sensible/sensitive and trustable (both in terms of reliability and privacy). We put forward the thesis that a more integral and social-aware sort of intelligence is needed to effectively interact, decide and act on behalf of people’s interest and that a way to test how effective systems are achieving these desirable behaviour is needed as a consequence. We support our thesis by providing examples on how to measure effectiveness in variety of different environments.

Estudio de las maquinas eléctricas para el ingeniero en electrónica

Tesis (Maestría en Ciencias de la Ingenieria Electrica con Especialidad en Electrónica) UANL

Utilización de la computadora como herramienta en el diseño de elementos de maquinas

Tesis (Maestro en Ciencias de la Ingeniería Mecánica con Especialidad en Diseño Mecánico) - Universidad Autónoma de Nuevo León, 2002

La logique ordinale de Turing

Le sujet visé par cette dissertation est la logique ordinale de Turing. Nous nous référons au texte original de Turing «Systems of logic based on ordinals» (Turing [1939]), la thèse que Turing rédigea à Princeton sous la direction du professeur Alonzo Church. Le principe d’une logique ordinale consiste à surmonter localement l’incomplétude gödelienne pour l’arithmétique par le biais de progressions d’axiomes récursivement consistantes. Étant donné son importance considérable pour la théorie de la calculabilité et les fondements des mathématiques, cette recherche méconnue de Turing mérite une attention particulière. Nous retraçons ici le projet d’une logique ordinale, de ses origines dans le théorème d’incomplétude de Gödel jusqu'à ses avancées dans les développements de la théorie de la calculabilité. Nous concluons par une discussion philosophique sur les fondements des mathématiques en fonction d’un point de vue finitiste.

La logique ordinale de Turing

Dans Systems of logic based on ordinals (1939), Turing explore les possibilités de minimiser les effets du théorème d’incomplétude pour l’arithmétique par le biais d’une logique ordinale. Nous rendons ici compte de cette recherche méconnue menée par Turing sur les fondements des mathématiques en replaçant ses apports dans le contexte actuel de la théorie de la calculabilité.

Turing Test: Mindless Game?

The Turing Test, originally configured for a human to distinguish between an unseen man and unseen woman through a text-based conversational measure of gender, is the ultimate test for thinking. So conceived Alan Turing when he replaced the woman with a machine. His assertion, that once a machine deceived a human judge into believing that they were the human, then that machine should be attributed with intelligence. But is the Turing Test nothing more than a mindless game? We present results from recent Loebner Prizes, a platform for the Turing Test, and find that machines in the contest appear conversationally worse rather than better, from 2004 to 2006, showing a downward trend in highest scores awarded to them by human judges. Thus the machines are not thinking in the same way as a human intelligent entity would.